Los Angeles, CA , May 09, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory Board Member. Dr. McCarthy will help Endonovo continue to advance their clinical pipeline forward and contribute to the strategic and clinical development oversight of the company.
Dr. McCarthy is a Urologist in North Carolina, currently serving as the robotic surgeon and Chairmen of the robotics committee at New Hanover Regional Medical Center. Dr. McCarthy received his Bachelor of Science from Coastal Carolina University in 1998, Master’s Degree of Science in Renal Physiology at University of Georgia in 2000 and Doctor of Osteopathic Medicine at Pikeville College School of Osteopathetic Medicine in 2004. Dr. McCarthy has performed over 800 surgical cases for six straight years with 150-200 robotic cases per year and over 1,200 robotic surgeries since completing his residency in 2005 at the POH Medical Center.
“I am honored to serve on the Scientific Advisory Board of Endonovo Therapeutics,” said Dr. McCarthy. “I look forward to helping the company as it works to advance products in the industry and improve the lives of post-operative patients.”
Alan Collier, Endonovo’s Chief Executive Officer, stated, " “We are confident Roc’s insights and experience will be a huge asset to Endonovo as we continue to develop our clinical programs and studies. Roc’s awards, activities and professional affiliations will prove invaluable as we continue to advance our leading product toward a national rollout and ultimately improve the lives of patients globally. I believe this is an important moment in our growth and I look forward to working with Dr. McCarthy to help further our goal of bringing differentiated treatments to patients and eliminating drugs to post-op patients.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com